New Delhi, August 04, 2018: Dr Reddy’s Laboratories on Wednesday announced the launch of generic version of Plaquenil, used to treat malaria, lupus erythematosus, and rheumatoid arthritis, in the US.
The launch follows approval of Hydroxychloroquine Sulfate tablets, a therapeutic equivalent generic version of Plaquenil, by the US Food and Drug Administration (USFDA), Dr Reddy’s Laboratories said in a BSE filing.
Quoting IMS Health data, Dr Reddy’s Laboratories, the Plaquenil brand and generic had US sales of approximately $215 million for the most recent twelve months ending in May 2018.
Dr Reddy’s said its product Hydroxychloroquine Sulfate tablets are available in 200 mg tablets in the bottle count sizes of 100 and 500 according to the reports published in business-standard.com.
Plaquenil is a trademark of Concordia International Corp.
Shares of Dr Reddy’s Laboratories were trading at Rs 2,293.95 apiece, down 1.11 per cent from the previous close on the BSE.
Mumbai, 14th May 2024 – As part of its dedication to exceptional patient care, American Oncology…
Mumbai, May 11, 2024: In a landmark move for Indian healthcare, the introduction of Second…
Bengaluru, May 08, 2024: Cancer remains the illness most feared across the globe. But to combat…
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…